Reliability of Whole Sentinel Lymph Node Analysis by One-Step Nucleic Acid Amplification for Intraoperative Diagnosis of Breast Cancer Metastases by Castellano, I et al.
 
 
 
 
This is an author version of the contribution published on: 
Questa è la versione dell’autore dell’opera: 
 Annals of Surgery 
Issue: Volume 255(2), February 2012, p 334–342, DOI 
10.1097/SLA.0b013e31823000ed 
 
The definitive version is available at: 
La versione definitiva è disponibile alla 
URL[http://journals.lww.com/annalsofsurgery/pages/articleviewer.aspx?year=2012
&issue=02000&article=00022&type=abstract 
Reliability of Whole Sentinel Lymph Node Analysis by One-
Step Nucleic Acid Amplification for Intraoperative Diagnosis of 
Breast Cancer Metastases 
 
Castellano, Isabella MD1,2; Macrì, Luigia MD1,2; Deambrogio, Cristina MD1; Balmativola, 
Davide MD1; Bussone, Riccardo MD2,3; Ala, Ada MD2,3; Coluccia, Claudio MD2,3; Sapino, 
Anna MD1,2 
 
 
 
1Department of Biomedical Sciences and Human Oncology, University of Turin, Turin, 
Italy, 
2Division of Surgery, 
3Breast Unit, Azienda Ospedaliera-Universitaria San Giovanni Battista, Molinette Hospital, 
Turin, Italy. 
 
Disclosure: The authors declare no conflicts of interest.  
 
Supported by Rete Oncologica Piemonte-Valle d'Aosta, PRIN 2008, AIRC 2011, 
Compagnia San Paolo, Cassa di Risparmio di Torino and Progetto Ricerca Sanitaria 
Finalizzata DD204/2009. 
 
 2
ABSTRACT 
 
Objective: To assess the reliability of using the One-Step Nucleic Acid Amplification 
(OSNA) assay as a single test on whole sentinel lymph nodes (SLN) as a method of 
intraoperative diagnosis and staging of SLNs in breast cancer. 
 
Background: Combining histological and molecular assessment of metastasis on the same 
SLN may not fully reproduce the actual load of cancer cells present in the SLN and create 
problems in decisions regarding axillary dissection. 
 
Methods: Selection criteria for the whole SLN OSNA test required that the primary tumor 
expressed CK19 in more than 80% of tumor cells. Imprint cytology analysis of SLNs was 
performed together with the OSNA. 
 
Results: Of the 279 patients enrolled for SLN evaluation, 123 gave consent to the OSNA 
protocol and 156 to the standard histology. Thirteen patients were excluded from OSNA 
evaluation because of low CK19 gene expression in the primary tumor; only 2.3% were 
truly negative. The kappa of concordance between the imprint cytology and OSNA results 
was 0.52. The rate of macrometastases determined by OSNA was 11% versus 20% 
determined by histology, whereas the rate of OSNA-micrometastases (18%) was 
significantly higher than that determined by histology (8%). The rate of SLN-negative 
cases was similar between the 2 protocols. Macrometastases correlated with the presence 
of vascular invasion in both protocols. The rate of axillary lymph node metastases was 
consistent with SLN tumor load. 
 
Conclusions: Intraoperative OSNA assay performed on the whole SLN gave objective and 
reproducible results that were useful for directing decisions regarding axillary dissection 
and for accurately defining the SLN stage. 
In recent years, sentinel lymph node (SLN) biopsy has replaced traditional axillary lymph 
node (ALN) dissection and has become the standard technique for node staging in 
patients with clinically negative axilla.1–4 The SLN is thoroughly examined to insure that 
metastasis is not overlooked. However, the lack of universally accepted guidelines for SLN 
analysis results in a wide heterogeneity in gross- and microsectioning procedures and 
variability in the use of immunohistochemistry for detecting minimal tumor load.5 Another 
problem is the inconsistency in the diagnoses of isolated tumor cells (ITCs) and 
micrometastases, which are based solely on the size of the SLN tumor seed.6,7 Recently, 
Turner et al 8 showed that the consistency in diagnosis was highly improved when not only 
the size but also the arrangement (single, confluent or clustered) of the metastatic cells 
was taken into account. However, the European Working Group for Breast Screening 
Pathology found that the Turner et al 8 system was less reliable when determining the 
involvement of SLNs in lobular carcinoma, which metastasizes as dispersed cells and thus 
can easily be underscored.9 Taken together, these data suggest that the morphological 
evaluation of SLNs is not a reliable method for determining the actual tumor load in breast 
cancer patients. 
 
Another challenge relates to the intraoperative assessment of SLNs; specifically, whether 
and how the pathological assessment is to be performed (for example, using frozen 
sections or imprint cytology and with or without rapid immunohistochemistry to detect 
epithelial markers).5 Although intraoperative diagnosis allows for immediate axillary 
dissection and avoids a second surgery, its sensitivity varies from 44% to 75% regardless 
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of the method used.10–13 Thus, many institutions avoid intraoperative SLN analysis and 
postpone the diagnosis by formalin-fixing and paraffin-embedding tissues. 
 
With this complex background, molecular tests based on the identification of tumor-specific 
mRNA markers have been developed.14–16 Several studies have demonstrated that 
molecular approaches, such as real-time PCR, show a high sensitivity and specificity when 
compared to traditional histopathological examination of SLNs.17,18 Comparing quantitative 
PCR with extensive histological sectioning under laboratory conditions the sensitivity of 
molecular methods varies from 91% to 97% and the specificity may be equal to 97%.19 
However, samples from the same node used partly for molecular analysis and partly for 
morphological analysis generate obvious discrepancies because of uneven tissue 
distribution.20,21 For example in a previous study, using a fixation procedure that preserved 
both morphology and high-quality mRNA, we demonstrated, for example, that when 
metastases >2 mm were located at a pole of a lymph node they might be missed by either 
hematoxylin & eosin (H&E), immunostaining or RT-PCR applied to samples obtained from 
the opposite pole of the same lymph node.21 This data is in line with a previous 
geometrical model, which showed that incomplete sectioning of the SLNs in extreme 
situations would almost completely miss metastases >2 mm which would be identified at 
best as ITC.22 
 
Thus, herein, we tested the One-Step Nucleic Acid Amplification (OSNA) molecular assay 
(Sysmex) on whole SLNs for intraoperative diagnosis. The OSNA assay quantitatively 
measures the presence of cytokeratin-19 (CK19) mRNA, which distinguishes the absence 
of metastases from the presence of either micro- or macrometastases in the SLN.23–26 The 
aim of our study was to assess the reliability of OSNA analysis of whole SLNs as 
compared to standard histological diagnoses of the SLN, taking into account the biological 
features of primary breast cancer and the non-SLN status when axillary dissection was 
performed. 
 
 
METHODS 
 
Case Series 
From January to October 2010, 412 patients with breast cancer underwent surgery at the 
Breast Unit of the Azienda Ospedaliera Universitaria San Giovanni Battista of Turin. 
Following a standard protocol for presurgical staging, patients underwent ultrasound (US) 
examination of the axilla.27 Two hundred seventy-six patients had fine needle aspiration 
(FNA) of  
ALNs deemed to be suspicious by US and 133 showed presence of cancer cells on the 
cytological smears. Two hundred seventy-nine patients who did not have suspicious ALNs 
upon US examination nor positive cytological smears were eligible for SLN biopsies (Fig. 
1). SLNs were identified using a combination of blue dye and radioactive isotopes.28,29 
Blue-stained nodes and nodes with high radioactive counts were considered SLNs. The 
mean number of SLNs per patient was 1.2. To avoid any contamination of the tissue 
specimens during tumor manipulation, SLNs were excised before primary tumor surgery 
and immediately sent to the pathology laboratory for examination. 
 
 
 
 
 4
 
Fig.1 Study flowchart shows the process of patient selection. LN, lymph node; ICC, immunocytochemistry; CB, core 
biopsy. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Patient Selection for Whole SLN Examination by OSNA 
 
The protocol for the whole SLN examination by OSNA was approved by the local ethical 
committee. Informed consent was obtained from all patients before inclusion in the current 
study. To be enrolled for whole SLN evaluation by OSNA, the primary tumor had to 
express CK19 in >80% of tumor cells, as the OSNA assay evaluates CK19 mRNA copy 
number, and the lack of CK19 protein expression has been reported in approximately 2% 
of breast cancer patients.30 The expression of CK19 (clone RCK108, Dako, Denmark A/S 
DK 2600 Glostrup, diluted 1:100) in primary tumors was determined by 
immunocytochemical (ICC) analysis of either histological sections of the core biopsy or 
H&E-stained smears obtained by FNA. 
 
Intraoperative Procedure for OSNA Analysis 
 
The fresh SLN was cleared from fat tissue, weighed and cut along the short axis to obtain 
gross sections of 2.0 mm in thickness and processed as illustrated in Fig. 2(A). Imprint 
cytology was performed by touching the 2 sides of the cut surfaces of each gross section 
onto clean slides. Two of these slides were then fixed in 95% ethanol and stained with 
rapid H&E, and 2 others were fixed in neutral buffered formalin for 5 minutes and 
subjected to rapid ICC through incubation with an anticytokeratin mouse monoclonal 
antibody (clone AE1/AE3, Ventana-Diapath, Tucson, AZ, USA, prediluted) for 5 minutes at 
37°C. After washing with PBS, the sections were incubated with EnVision, 
DakoCytomation (Dako, Denmark, Glostrup) for 9 minutes at 37°C. Sections were then 
treated with diaminobenzidine tetrahydrochloride and counter-stained with hematoxylin. In 
the meantime the imprint cytology smears were stained, the SLNs were processed for 
OSNA. The minimum weight of the SLN for 1 OSNA reaction was 50 mg and the 
maximum was 600 mg. For SLNs exceeding 600 mg, 2 OSNA reactions were performed. 
SLNs were homogenized in 4 ml lysis buffer (Lynorhag, Sysmex, Kobe, Japan) for 90 
seconds on ice with a Politron PT1200-E homogenizer (Kinematica, Lucerne, Switzerland). 
The homogenate was centrifuged at 10,000g at room temperature for 1 minute, and 20-µL 
aliquots were used as a template for the reverse transcription loop-mediated isothermal 
amplification (RT-LAMP) reaction. To determine CK19 mRNA levels RT-LAMP was 
performed on an RD-100i automated mRNA amplification instrument (Sysmex, Kobe, 
Japan) with a ready-to-use reagent kit (Lynoamp, Sysmex) consisting of the enzyme, 
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primers, nucleotides, buffer necessary for CK19 mRNA amplification and components for 
assay validation (calibrators, positive and negative controls). 
 
 
 
 
Fig.2 Preparation of the sentinel lymph node (SNL) for evaluation by OSNA and imprint cytology (A) and 
standard histopathological techniques (B). The SNL was cut along the short axis to obtain gross sections of 
2.0 mm in thickness. (A) Imprint cytology was performed by touching the 2 sides of the cut surfaces of each 
gross section onto slides. Two of these slides were then fixed in 95% ethanol and stained with rapid 
hematoxylin and eosin (H&E), and 2 were fixed in neutral buffered formalin and tested by rapid 
immunocytochemistry with anti-AE1/AE3 antibodies. The whole SLN was examined by OSNA. (B) The gross 
sections were placed in bioboxes, formalin-fixed and paraffin-embedded. Each SLN was then step-sectioned 
at 100-μm intervals until the extinction of the wax blocks. The first 2 consecutive sections for each step were 
used for H&E staining and immunohistochemistry with anti-AE1/AE3 antibodies. 
 
Results were expressed as the number of CK19 mRNA copies per microliters, and 
metastatic load was assessed in accordance with the cut-off levels defined by Tsujimoto et 
al.26 On the basis of the values obtained using the standard curve, the (+) symbol 
corresponded to 250 to 5000 CK19 mRNA copies/µL and was defined as 
“micrometastases,” and the (++) symbol corresponded to >5000 CK19 mRNA copies/µL 
and was defined as “metastases.” A negative result (–) had less than 250 CK19 mRNA 
copies/µL and reflected the absence of cancer cells or the presence of ITC. The OSNA 
instrument software displayed (ND) in samples with no CK19 mRNA and (L) when the 
CK19 mRNA copy number was between 100 and 250 copies/µL. The symbol (I) appeared 
when the analysis was being performed on a sample previously diluted 1:10 in lynorhag 
solution. These diluted samples were prepared for each case to limit the activity of 
substances that could inhibit the amplification, such as an excess of adipose tissue. 
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Management of Patients after OSNA Examination 
 
The surgical management of the patients with regard to ALN dissection after whole SLN 
examination by OSNA was discussed and approved by the surgeons and oncologists of 
the breast unit (Fig. 3). For the study purposes, patients with macrometastases 
(determined by OSNA and non-OSNA) or micrometastases determined by OSNA and 
associated with a positive imprint cytological analysis underwent immediate ALN 
dissection. In the other cases of micrometastases ALN dissection was postponed until 
evaluation of the biological features of the primary tumor (diameter, grade, vascular 
invasion) at multidisciplinary discussions. Finally, ALN dissection was not recommended 
for patients with AE1/AE3-positive cells as determined by imprint cytology, patients that 
had negative SLN results by OSNA or patients with ITCs detected by standard histological 
examination. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3 
Surgical management of patients after diagnosis by OSNA or with standard histology. Patients with 
macrometastases (determined by OSNA and non-OSNA) or micrometastases determined by OSNA and a 
positive imprint cytological analysis underwent immediate axillary dissection. For patients with 
micrometastases (determined by OSNA and non-OSNA) or a positive imprint cytological analysis 
(hematoxylin and eosin [H&E]+ immunocytochemistry (ICC), axillary dissection was postponed after 
multidisciplinary discussions. Patients with OSNA-negative SLNs or Isolated Tumor cells (ITCs) detected by 
standard histological analysis were not recommended to undergo axillary dissection. 
 
Real Time-PCR of Discordant Cases 
 
Total RNA was extracted from samples with discordant results between imprint cytology 
and OSNA analyses with the RNeasy mini-kit (Qiagen, Hilden, Germany) according to the 
manufacturer's instructions. Quantitative RT–PCR was performed using the breast cancer 
markers, CK19 and SPDEF (SAM pointed domain containing Ets transcription factor), and 
beta-actin as a control as described in detail elsewhere.24–26 The cut-off levels previously 
suggested 24 and expressed in threshold cycles (Ct) were as follows: 31.5 for CK19 and 
31.6 for SPDEF. Cases with a Ct value 2 times lower than the cut-off were considered as 
positive, cases with value 2 times higher than the Ct were considered as negative; cases 
in between were considered as borderline. 
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Standard SLN Processing 
 
Following a protocol proposed by the regional section of the Italian Society of Pathology, 
31 no intraoperative diagnosis was performed, and the SLN was processed for standard 
histological examination (Fig. 2B). Fresh SLNs were sliced at 2.0 mm as reported above. 
The gross sections were placed in bioboxes and formalin-fixed. When embedding the 
samples in paraffin wax, care was taken to preserve the original sequence of slices so that 
the top cut surface of a gross section and the bottom surface of the next section 
represented contiguous areas of the SLN. Each SLN was then step-sectioned at 100-µm 
intervals until the extinction of the wax blocks. The first 2 consecutive sections were used 
for H&E staining and ICC analysis with AE1/AE3 anti-cytokeratin antibodies (clones 
AE1/AE3 & PCK26, Ventana-Diapath, prediluted) using the BenchMark AutoStainer 
(Ventana Medical Systems). 
 
Metastatic deposits were measured in 2 dimensions and categorized based on the staging 
system established by the American Joint Committee on Cancer.7 The categories were as 
follows: pN0(i+), malignant cells <0.2 mm, single tumor cells or a cluster of <200 cells in a 
single histologic cross-section (including ITCs); pN1mi, micrometastases >0.2 mm and/or 
>200 cells, but not >2.0 mm and pN1a, metastases in 1 to 3 ALNs or at least 1 metastasis 
>2.0 mm. 
 
ALNs were isolated from the fat tissue and grossly sliced at 2.0 mm intervals if larger than 
0.5 cm similarly to the SLNs. Two H&E stained sections were produced for each block. 
 
Data Analysis 
 
The concordance between cytological analysis on imprint, considered as the “gold 
standard,” and the OSNA analysis was calculated using the Cohen's K statistic (for that 
purpose, to compare the same number of categories within the cytological imprint 
diagnosis and the OSNA assay results, macrometastases and micrometastases cases 
were merged into a single positive category). Sensitivity, specificity and positive and 
negative predictive values of OSNA were calculated. 
 
The primary tumor variables listed in Table 1 and the ALN status were compared with the 
OSNA and non-OSNA results using the [chi]2 test. P values <0.05 were considered 
statistically significant. 
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TABLE 1. Comparison of Primary Tumor Features of the 2 Series of Patients 
 
RESULTS 
 
Of 279 patients enrolled for SLN procedure, 123 patients gave their consent to participate 
in OSNA analysis (44%). Of these, 13 patients were excluded because the primary tumor 
was either negative for (3 cases) or expressed low levels of (10 cases) CK19 and the SLN 
was thus evaluated by traditional histology (Fig. 1). The remaining 156 (56%) patients 
were evaluated using standard histological examination of SLNs (Fig. 1). The 
histopathological parameters of the tumors of patients participating and nonparticipating to 
the OSNA analysis were compared (Table 1). Although the patient and tumor 
characteristics did not differ statistically between the 2 groups, the patients were not 
selected randomly and the numbers were too small to exclude that differences not 
represented by the statistics may exist. 
 
Correlation of OSNA with Imprint Cytology 
 
A total of 131 SLNs from 110 patients were examined by OSNA. Three patients had 
bilateral disease and the SLNs on each side were studied. The H&E diagnosis matched 
perfectly with the ICC diagnosis on imprint cytology. The concordance between imprint 
cytology and OSNA analyses gave a Cohen's K statistic of 0.52 (Table 2). The OSNA 
procedure showed 93.75% sensitivity, 83.47% specificity, 0.44 positive predictive value 
and 0.99 negative predictive value. 
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TABLE 2. Contingency Table and Concordance Between OSNA Assay Results and 
Cytological Imprint Diagnosis of 131 SLN Examined 
 
 
 
 
Of the 20 discordant cases, the 2 OSNA-diagnosed macro-metastases and 9 
micrometastases, which were negative by imprint cytology, were positive for CK19 and/or 
SPDEF by real-time PCR (Table 3); 8 samples with micrometastases had “borderline” Ct. 
One single sample (L71), which was H&E/ICC-positive and OSNA-negative, was positive 
by real-time PCR. This case was designated by the OSNA instrument software as (L), 
meaning that the CK19 mRNA copy number was not 0 but between 100 and 250 
copies/µL. The ALNs of sample L71 were not metastatic. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 3. SYBR-Green Real-Time PCR Analyses of the 20 Samples that Showed 
Discordant Results Between Imprint Cytology and OSNA 
 
 
 
 
 10
 
 
 
 
Comparison between OSNA and Standard Histology Techniques 
 
As shown in Table 4, the rate of negative cases determined by standard histology 
(negative + ITC) (73%) was highly comparable with the rate of negative SLNs determined 
by OSNA (71%). The percentage of micrometastases detected by OSNA was instead 
significantly higher (18%) than that determined by the standard procedure (8%; [chi]2 7.03; 
P < 0.01), on the contrary the rate of macrometastases detected by OSNA was lower 
(11%) but was not significantly different from that determined by standard histology (20%). 
The presence of macrometastases significantly correlated with vascular invasion ([chi]2 
21.34; P < 0.01 and [chi]2 21.79; P < 0.01), and similarly, the absence of metastases 
correlated with the absence of vascular invasion in both protocols ([chi]2 15.21; P < 0.01 
and [chi]2 20.82; P < 0.01). No significant difference was observed in the rate of metastatic 
ALNs after the diagnoses of micro- and macrometastases in SLNs either by OSNA or 
standard procedure (Table 5). 
 
 
 
TABLE 4. Comparison of Histopathological Parameters of Primary Breast Cancer of 
Patients Enrolled to OSNA and to Standard Histopathology Examination of Sentinel Lymph 
Node 
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TABLE 5. Comparison Between OSNA Assay Results and Standard Histology in the 
Involvement of Non-Sentinel Lymph Node 
 
 
DISCUSSION 
 
This work demonstrated that the OSNA assay may be reliably used for intraoperative 
diagnosis of patients with breast cancer using the whole SLN for analysis. The OSNA 
protocol was discussed with surgeons, as well as with oncologists, because the SLN could 
be the only lymph node with metastases, and thus, the use of the OSNA procedure 
influenced not only the surgical but also the medical management acting on the patient risk 
category.32 In recent years, several studies have proposed procedures for molecular-
based detection of metastasis with proper calibration for intraoperative diagnosis of the 
SLN in breast cancer.33–36 In particular, the OSNA assay evaluates the number of mRNA 
copies of CK19, an epithelial marker highly expressed in the majority of breast cancers. 
Different protocols have been designed to determine the sensitivity and specificity of the 
OSNA assay for the detection of metastasis in comparison with histological 
examination.20,23–26 These protocols recommend subdividing the single SLN into gross 
sections to be used for both molecular and histological diagnosis.20,23–26 Previously, we 
have shown the technical limits of histological- and of molecular-based diagnoses 
performed on microsections of the same SLN. These limits depend not only on the 
diameter but also on the location of metastases.21 The tissue allocation bias has been 
regarded as one of the main causes of discordance when comparing the 2 
procedures.20,21 However, it has never been discussed whether the micrometastases 
detected on a sample by molecular assay should be added, for example, to the 
micrometastases diagnosed by standard histology on the parallel sample of the same SLN 
to obtain a final evaluation of the tumor burden. These variables may impact heavily on 
nodal staging of the SLN, because variations in the dimension of the metastasis in the 
range of microns or a tenth of cells may move a patient from the pN0 (absence of 
metastases) to the pN1 (presence of metastases) stage and vice versa. This study 
proposes that the molecular analysis of the whole SLN would avoid these biases and allow 
a less subjective evaluation of the metastatic tumor load. In fact, the OSNA assay is a 
system for rapid and quantitative detection of CK19 mRNA,26 which guarantees a high 
specificity with a low false-positive rate. The rate of micrometastases detected by OSNA in 
this study was significantly higher than that detected by standard histology, whereas the 
rate of OSNA-determined macrometastases was lower. The difference of micro- versus 
macrometastases between the 2 groups may be a reflection of different patient 
populations rather than a reflection of the different techniques of analysis of the SLN. 
However, because the percentage of negative cases was similar between the 2 protocols 
our data may suggest the hypothesis that the morphological evaluation of the diameter of 
metastases does not perfectly correlate with the tumor load as evaluated by mRNA copies 
of CK19, and that, at least in our series, there could be either an overestimation of the 
macro- versus micrometastases by histology or an underestimation of the macro- versus 
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micrometastases by OSNA. This is quite important because recent studies show that ALN 
dissection is not mandatory in the presence of micrometastases at difference with the 
presence of macrometastases.37–39 Up to now the volume of metastatic disease evaluated 
by molecular analysis that would require an axillary dissection has not been established 
and only recurrence and survival data will clarify it. In addition, the OSNA assay does not 
provide any data about the presence of ITCs, however follow-up studies have shown that 
patients with ITCs have locoregional recurrence rates very similar to SLN-negative 
cases.40 
   
 
A major problem associated with the analysis of the whole SLN by OSNA may be the risk 
of false negative results due to the presence of metastases from breast cancers that do 
not express CK19. For this reason, we required that the expression of CK19 by the 
primary tumor be a prerequisite for patients participating in the OSNA analysis, although 
the ICC pre-test added minimal cost to the procedure. The lack of CK19 protein 
expression has been reported in approximately 2% of breast cancers.30 We confirmed this 
result, finding that 2.8% of the cases in our series were truly negative. Cases that showed 
<20% of cells positive for CK19 were probably the result of poor-quality ICC performed on 
smears that had been previously stained with H&E, as indicated by the high level of CK19 
expression subsequently observed on surgical samples of the primary tumors (data not 
shown). Furthermore, to verify the OSNA results, we performed touch imprint cytology for 
every SLN. Imprint cytology failed to show metastatic involvement in 58% of OSNA-
positive SLNs. This result is in agreement with those reported by Layfiel MD and 
colleagues 19 in a recent review. The authors concluded that “pathological techniques of 
intraoperative SLNB analysis such as touch imprint cytology and frozen section have a 
high specificity, but a lower and more variably reported sensitivity. Molecular techniques 
are potentially able to sample a greater proportion of the sentinel node, and could have 
higher sensitivity.”19 A possible justification of the result we obtained is that 90% of 
discordant cases were diagnosed as micrometastasis by the OSNA assay, suggesting that 
imprint cytology may under diagnose low tumor burden in the SLN.41–44 Nevertheless, 
imprint cytology is useful in conjunction with the whole SLN-OSNA assay to check for 
other diseases, such as lymphomas, or to determine the presence of metastases of other 
tumors, such as melanomas. 
   
 
The rate of metastases in ALNs excised after a positive SLN was not significantly different 
between patients in the OSNA group and in the standard histology group, and this rate 
was consistent with that reported in previous studies.40 
   
 
Finally, a cost analysis assessment of the OSNA technique was performed at a large UK 
district general hospital and indicated that there was an implicit savings in reducing the 
number of secondary surgeries, such as reduced bed occupancy, and this savings may 
comfortably offset the expense of intraoperative molecular analysis.45 Another way to allow 
intraoperative axillary dissection to proceed would be to improve on the intraoperative, 
cryostat section diagnosis; however frozen sections, have a sensitivity that range from 
17% to 92% for micrometastases and from 84% to 94% for macromestastases 19 and do 
require well trained laboratory technicians. 
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In conclusion, an intraoperative OSNA assay performed on the whole SLN gives objective 
and reproducible results that can be used for proceeding for axillary dissection in a single 
surgical session. In addition, the more accurate evaluation of tumor load in the SLN 
provides a valuable tool for assessing the risk category of patients with breast cancer and 
in turn for defining the oncological therapy. 
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